Lung Cancer News and Research

Latest Lung Cancer News and Research

Today's Op-Eds: Congress needs conservative leadership; reviving tort reform; can states afford to drop Medicaid?

Nothing has gone quite so awry as the massive, government-run Obama health program, and it is plain that the individual mandate, the employee mandate, the abortion funding, the tangle of outsider/insider councils like the comparative effectiveness board and the effective nationalization of healthcare under grants of authority to the Department of Health and Human Services.

16 Nov 2010

Urgent need for bowel cancer screening funding

Bowel Cancer Foundation chairman, Graham Newstead feeling frustrated at the federal government’s indecision on bowel cancer screening funds has expressed his dismay. He suggested that the government should ensure the future funding for the screening test that has saved an estimated 11,000 lives since screening was introduced in 2006.

16 Nov 2010

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 International Pharmaceutical Federation Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition in New Orleans, La., Nov. 14-18.

16 Nov 2010

Graphic images of negative consequences of smoking have greatest impact on smokers

Marketing researchers at the University of Arkansas, Villanova University and Marquette University surveyed more than 500 U.S. and Canadian smokers and found that the highly graphic images of the negative consequences of smoking have the greatest impact on smokers' intentions to quit. The most graphic images, such as those showing severe mouth diseases, including disfigured, blackened and cancerous tissue, evoked fear about the consequences of smoking and thus influenced consumer intentions to quit.

15 Nov 2010

SuperGen to present three abstracts at EORTC-NCI-AACR International Symposium

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts detailing recent work with SuperGen compounds.

15 Nov 2010

Cerulean closes $24 million Series C financing by Lilly Ventures

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company has closed a $24 million Series C financing led by Lilly Ventures, with participation from all other existing investors including Polaris Venture Partners, Venrock, Lux Capital, and Bessemer Venture Partners.

15 Nov 2010

ICON, Proteome enter alliance to provide expanded biomarker solutions

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Proteome Sciences a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

15 Nov 2010

Women and cancer today

Experts have warned that women who have their breasts removed out of fear of a high hereditary risk of breast cancer may be doing so needlessly. Genetic tests like for the BRCA mutations have predicted a high risk of getting breast cancer in women with many breast cancer sufferers among their first degree relatives. Earlier studies suggest the risk of the mutation to predict the cancer 87% of the time. Now experts want that this is an overestimate.

11 Nov 2010

Dead litigant’s family bullied by tobacco company

In 2002 Jamie McCabe’s mother Rolah won a landmark legal battle against British American Tobacco and alleges that the family is still being harassed by the tobacco giant. Ms McCabe became the first Australian to successfully sue a tobacco company. She won $700,000 in compensation after Justice Geoffrey Eames, in the Victorian Supreme Court, found the tobacco company had destroyed potentially relevant documents about the damaging effects of smoking.

11 Nov 2010

USPTO issues Notice of Allowance to Asuragen’s mir-205 for lung cancer diagnosis

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today that it had received a Notice of Allowance from the United States Patent and Trademark Office for claims related to the use of mir-205 as a diagnostic in lung cancer.

11 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

Dana-Farber lends iPads to cancer patients to help them pass the time in clinic

Andrea Casella comes to Dana-Farber Cancer Institute every week for chemotherapy to treat her lung cancer. It's a full day. Recognizing that patients can spend hours in the clinic for treatment and tests, Dana-Farber has started lending iPads to patients like Casella to help them pass the time.

11 Nov 2010

Legacy applauds HHS and FDA for new tobacco control strategic action plan

Legacy applauds HHS Secretary Kathleen Sebelius and the leadership at the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) for its bold new effort announced today to dramatically reduce the number of American lives lost annually to tobacco-related disease. Still the number one preventable cause of death, tobacco continues to claim more than 400,000 lives each year in the United States.

11 Nov 2010

Lung cancer in smokers versus non-smokers shows different genetic mutations

A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, “At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes.” The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.

10 Nov 2010

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its real-time PCR-based Epidermal Growth Factor Receptor Assay (the "EGFR PCR Assay") for the use of lung cancer targeted drugs from the State Food and Drug Administration of China (the "SFDA").

10 Nov 2010

Study finds different DNA alterations in tumor genomes of smokers and never-smokers

Lung tumors in those who smoke and those who never smoked have different DNA alterations in the tumor genomes, according to results of a pilot study presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Home smoking restrictions needed to reduce tobacco-related carcinogens in children's urine

Ninety percent of children who lived in a house where an adult smoked had evidence of tobacco-related carcinogens in their urine, according to research presented at the Ninth AACR Frontiers in Cancer Prevention Research Conference, held here from Nov 7-10, 2010.

10 Nov 2010

Younger patients unable to cope with pain and emotional issues of cancer

Younger adult cancer patients have the most difficulty coping with the pain and emotional issues of cancer, in spite of their potentially better survival odds, according to a University of Michigan Health System study.

10 Nov 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010 and provided an update on corporate developments.

9 Nov 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Today's Op-Eds: Congress needs conservative leadership; reviving tort reform; can states afford to drop Medicaid?

Urgent need for bowel cancer screening funding

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

Graphic images of negative consequences of smoking have greatest impact on smokers

SuperGen to present three abstracts at EORTC-NCI-AACR International Symposium

Cerulean closes $24 million Series C financing by Lilly Ventures

ICON, Proteome enter alliance to provide expanded biomarker solutions

Women and cancer today

Dead litigant’s family bullied by tobacco company

USPTO issues Notice of Allowance to Asuragen’s mir-205 for lung cancer diagnosis

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Dana-Farber lends iPads to cancer patients to help them pass the time in clinic

Legacy applauds HHS and FDA for new tobacco control strategic action plan

Lung cancer in smokers versus non-smokers shows different genetic mutations

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

Study finds different DNA alterations in tumor genomes of smokers and never-smokers

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Home smoking restrictions needed to reduce tobacco-related carcinogens in children's urine

Younger patients unable to cope with pain and emotional issues of cancer

ARIAD reports $20.4 million net loss for third quarter 2010

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in